## **Laboratory News**

VOL. 47, NO. 4 - February 8, 2024

## Microbiology Lab Update

Modifications to AST panel for staphylococcal isolates

On or about March 4, 2024 our AST panels for staphylococcal isolates will be modified as follows:

Ceftaroline will no longer be reported on MRSA.

Levofloxacin and penicillin will no longer be reported on all staphylococci.

For our current panels see the following:

MCHS

Current Antimicrobial Susceptibility Test Panels (MCHS).

Table: New staphylococcal AST panels; reported drugs are denoted by an "X".

| Antimicrobial      | New Panel |
|--------------------|-----------|
| Clindamycin [1]    | Х         |
| Daptomycin         | (X)       |
| Erythromycin [1]   | X         |
| Linezolid          | (X)       |
| Nitrofurantoin [2] | Х         |
| Oxacillin          | X         |
| Rifampin           | X         |
| Tetracycline       | Х         |
| Trim/Sulfa         | Х         |
| Vancomycin         | Х         |

<sup>&</sup>quot;()" denotes a cascaded drug that is reported only when specific narrow spectrum agents are resistant.

These changes have been made following the latest standards from the Clinical and Laboratory Standards Institute and with input from our antimicrobial stewardship committee, pharmacy and the infectious diseases service.

Please contact Dr. Thomas Novicki or Dr. Sophie Arbefeville at (ext. 16100) for questions.



<sup>[1]</sup> Non-urine isolates only.

<sup>[2]</sup> Urine isolates only.